Tissue Acquisition in Clinical Trials-Essential for Progress

Affiliations

¹ Investigational Drug Branch, Cancer Therapy Evaluation Program (SPI), Cancer Therapy Evaluation Program (JSA), Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Comment

S Percy Ivy et al. J Natl Cancer Inst. 2017.

. 2017 Apr 1;109(4):djx003.

doi: 10.1093/jnci/djx003.

¹ Investigational Drug Branch, Cancer Therapy Evaluation Program (SPI), Cancer Therapy Evaluation Program (JSA), Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

No abstract available

Comment on

Burdensome Research Procedures in Trials: Why Less Is More.
Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ. Kimmelman J, et al. J Natl Cancer Inst. 2017 Apr 1;109(4):djw315. doi: 10.1093/jnci/djw315. J Natl Cancer Inst. 2017. PMID: 28376159 Free PMC article.

1. Kimmelman et al. Burdensome research procedures in trials: Why less is more. J Natl Cancer Inst. 2017;1094:djw315. - PMC - PubMed
1. Gabriel N., Hortobagyi MD.. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734–1736. - PubMed
1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. - PubMed
1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364:2507–2516. - PMC - PubMed
1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. - PubMed